HIV-associated lipodystrophy syndrome: Description and pathogenesis

Journal of Infection

Volumn 46, Issue 3, 2003, Pages 149-154

  Bodasing, N ^a   Fox, R ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E2; HIGH DENSITY LIPOPROTEIN; INDINAVIR; INSULIN; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRASTERONE; PROTEINASE INHIBITOR; RETINOIC ACID BINDING PROTEIN; RETINOID X RECEPTOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMINAL DISTENSION; BODY BUILD; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; GENETIC PREDISPOSITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOPATHOLOGY; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; MYOPATHY; NONHUMAN; PANCREATITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; REVIEW; RISK FACTOR;

EID: 0037382460     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2002.1102     Document Type: Review

References (67)

1. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
2. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-875.
3. Lo JC, Mulligan K, Tai VW et al. Buffalo Hump in HIV infected patients on antiretroviral therapy. Lancet 1998; 351: 861-870.
4. Carter VM, Hoy JF, Bailey M et al. The prevalence of lipodystrophy in an ambulant HIV-infected poulation: it all depends on the definition. HIV Med 2001; 2: 174-180.
5. Grunfeld C. Basic science and metabolic disturbances. Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract TuOr158.
6. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985; 42: 1255-1256.
7. Saint-Marc T, Partisani M, Poizot-Martin I et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14: 37-49.
8. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
9. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 79: 1045-1052.
10. Fernandez-Miranda C, Pulido F, Carrillo JL, et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin Chim Acta 1998; 274: 63-70.
11. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
12. Hellerstein MK, Grunfeld C, Wu K et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infected humans. J Endocrinol Metab 1993; 76: 559-565.
13. Grunfeld C, Kotler DP, Shigenaga JK et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90: 154-162.
14. Stein TP, Nutinsky C, Condolvei D, Sshulter MD, Leskin MJ. Protein and energy substrate metabolism in AIDS patients. Metabolism 1990; 39: 876-881.
15. Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991; 40: 651-656.
16. Shikuma CM, Waslien C, McKeague J et al. Fasting hyper-insulinemia and increased waisit-to-hip ratios in non-wasting individuals with AIDS. AIDS 1999; 13: 1359-1365.
17. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84: 1932-1937.
18. Behrens G, Dejam. A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-F70.
19. Purnell JQ, Zambon A, Knopp RH et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 51-57.
20. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors is associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1 infected patients. AIDS 1998; 12: F167-F173.
21. Bernasconi E, Carota A, Magenta L et al. Metabolic changes in HIV-infected patients treated with protease inhibitors. Program and Abstracts of the 12th World AIDS Conference, June 29-July 3 1998, Geneva, Switzerland. Abstract 12375.
22. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700-705.
23. Sergerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidaemia under treatment with protease inhibitors. Infection 1999; 27: 77-81.
24. Petit JM, Duong M, Duvillard L et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Horm Metab Res 2000; 32: 367-372.
25. Montserrat SR, Pena R, Cervantes M et al. Hyperglycaemia associated with protease inhibitor therapy. Program and Abstracts of XII International Conference on AIDS. 28 June-3 July 1998, Geneva, Poster 12387.
26. Lumpkin MM. Reports of diabetes and hyperglycaemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus. FDA Public Health Advisory, June 11, 1997.
27. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160: 2050-2056.
28. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-810.
29. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 352: 1881-1883.
30. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPAR-gamma/RXR heterodimer. J Endocrinol 2000; 164: R7-R10.
31. Zhang B, MacNaul K, Szalkowski D, Li Z, Berger J, Moller DE. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999; 84: 4274-4277.
32. Sakai J, Rawson RB. The sterol regulatory element-binding protein pathway: control of lipid homeostasis through regulated intracellular transport. Curr Opin Lipidol 2001; 12: 261-266.
33. Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor-induced hyperlipidaemia and lipodystrophy is mediated through regulation of sterol responsive element-binding protein (SREPB) responsive genes. Circulation 2000; 102(Suppl. 11): 352-360.
34. Andre P, Groettrup M, Klenerman P et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998; 95: 13120-13124.
35. Liang JS, Distler O, Cooper DA et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001: 7: 1327-1331.
36. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 1378-1388.
37. Ledru E, Christeff N, Patey O, De Truchis P, Melchior JC, Gougeon ML. Alteration of tumour necrosis factor-alpha T-cell hoemeostasis following potent antiretroviral therapy: contribution to the developement of human immunodefieiency virus-associated lipodystrophy syndrome. Blood 2000; 95: 3191-3198.
38. Mynarcik DC, McNurlan NA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumour necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immun Def Syndr 2000; 25: 312-321.
39. Ionescu G, He Q, Engelson ES et al. Acylation stimulating protein (ASP) and tumour necrosis factor (TNF) production in subcutaneous adipose tissue of HIV-infected patients with and without lipodystrophy. Program and Abstracts of the XIV International AIDS Conference, June 7-12, 2002, Barcelona. Abstract WePeA5794.
40. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997; 350: 713-714.
41. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-20254.
42. Nolte LA, Yarasheski KE, Kawanaka K, Fisher J, Le N, Holloszy JO. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001; 50: 1397-1401.
43. Gervasoni C, Ridolfo AL, Trifiro, G et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13: 465-471.
44. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS 1999; 13: 735-737.
45. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleopside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-1115.
46. Silvestri G, Ciafaloni E, Santorelli FM et al. Clinical features associated with the A → G transition at nucleotide 8344 of mtDNA ("MERRF mutation"). Neurology 1993; 43: 1200-1206.
47. Enzi G, Inelmen EM, Baritussio A, Dorigo P, Prosdocimi M, Mazzoleni F. Multiple symmetric lipomatosis: a defect in adrenergic-stimulated lipolysis. J Clin Invest 1977; 60: 1221-1229.
48. Christeff N, Melchior JC, Mammes O, Gherbi N, Dalle MT, Nunez EA. Correlation between increased cortisol:DHEA ratio and malnutrition in HIV-positive men. Nutrition 1999; 15: 534-539.
49. Nunez EA, Christeff N. Steroid hormones, cytokines, lipid and metabolic disturbances in HIV infection. The Endocrinology and Metabolism, of HIV Infection 1994; Balliere and Tindall, 803-824.
50. Christeff N, Gharakhanian S, Thobie N, Rozenbaum W, Nunez EA. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immun Def Syndr 1992; 5: 841-846.
51. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999; 13: 2251-2260.
52. Shepherd A, Cleay MP. Metabolic alteration after dehyroepiandrosterone treatment in Zucker rats. Am J Physiol 1984; 246: E123-E128.
53. Yanovski JA, Miller KD, Kino T et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999; 84: 1925-1931.
54. Grunfeld C, Doerrlor W, Pang M et al. Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1997; 82: 3734-3740.
55. Lister RK, Youle M, Nair DR, Winder AF, Rustin MH. Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet 1999; 353: 1678.
56. Fauvel J, Bonnet E, Ruidavets JB et al. An interaction between apo-C-III variants and protease inhibitors contributes to high triglycerides/low HDL levels intreated patients. AIDS 2001; 15: 2397-2406.
57. Mallal S, John M, Moore C et al. Protease inhibitors and NRTI reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection. Antiviral Therp 1999; 4(Suppl. 2): 28-29.
58. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor - related lipodystrophy syndrome. AIDS 2000; 14: F25-F32.
59. Sutinen J, Mathur-wagh U. Changes in body shape during PI therapy in HIV +ve women. Program and Abstracts of 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4, 1999. Abstract 662.
60. Saint-Marc T, Touraine EL. Buffalo Hump in HIV infection. Lancet 2002; 352: 319-320.
61. Rosenberg BE, Mulder J, Sepokowitz KA, Giordano MF. "Protease paunch" in HIV +ve persons receiving protease inhibitor therapy:incidence, risk and endocrinologic evaluation. Program and Abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago. Abstract 408.
62. Boix V, Reus S, Priego M et al. Expanding the spectrum of protease inhibitors-induced lipodystrophy. Program and Abstracts of 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. Abstract 12398.
63. Reboli AC, Marshall S. Changes in body habitus in HIV infected patients treated with protease inhibitors. Infectious Diseases Society of America 36th Annual Meeting, November 12-15, 1998, Denver. Abstract 476 Sa.
64. Dong K, Bausserman LL, Flynn MM et al. Changes in body habitus and serum lipid abnormalities in HIV +ve women on highly active antiretroviral therapy. J Acquir Immun Def Syndr Retrovirol 1999; 21: 107-113.
65. Lui A, Karter D, Turrett G. Another case of breast hypertrophy in a patient treated with Indinavir. Clin Infect Dis 1998; 26: 1482.
66. Wong KH, Ho Ty, Chan CW, Lee SS. Indinavir associated facial atrophy in HIV positive patients. Program and abstracts of 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. Abstract 12391.
67. Viraben R, Aquuilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12: F37-F39.